王红艳;杨月;刘野;刘金丽;郭素芬;

• 1:牡丹江医学院病理教研室
• 2:牡丹江市第二人民医院病理科

摘要(Abstract)：

目的本研究主要探讨Nanog蛋白与肿瘤微血管密度(MVD)在各级别乳腺浸润性导管癌,非特殊类型(invasive ductal carcinoma,no special type,IDC-NST)中的表达及其相关性。方法应用免疫组织化学染色法(Immunohistochemistry,IHC)检测乳腺浸润性导管癌组织和癌旁正常乳腺组织中Nanog蛋白的表达情况,分析其与临床相关病理特征(患者年龄、月经状况、肿物大小、病理学分级、TNM分期)的关系,并观察微血管的生成情况,分析Nanog的表达与MVD的相关性。结果 Nanog蛋白在乳腺癌组织中的表达明显高于癌旁正常乳腺组织,差异显著(χ²=32.069,P<0.001)具有统计学意义;乳腺癌Nanog蛋白的表达与被检测标本者的年龄大小、月经状况及肿物大小无明显相关,而与淋巴结转移情况以及病理学分级、TNM分期相关;乳腺癌中MVD的增加与Nanog表达呈正相关。结论乳腺癌中Nanog的表达及MVD均与乳腺癌病理组织学分级、TNM分期、淋巴结转移相关;并且Nanog与MVD呈正相关;Nanog和MVD联合检测有望成为乳腺癌诊疗及判断预后新指标。

关键词(KeyWords)： 乳腺癌;Nanog;微血管密度;CD34;相关性

Abstract:

Keywords:

基金项目(Foundation): 黑龙江省自然基金(LH2019H119);; 黑龙江省高校基本科研业务费(2018-KYYWFMY-0006);; 牡丹江医学院研究生创新基金(2019YJSCX-01MY)

作者(Authors): 王红艳;杨月;刘野;刘金丽;郭素芬;

DOI: 10.13799/j.cnki.mdjyxyxb.2020.02.005

参考文献(References)：

• [1] SEYMOUR T,TWIGGER A J,KAKULAS F.Pluripotency Genes and Their Functions in the Normal and Aberrant Breast and Brain[J].Int J Mol Sci,2015,16(11):27288-27301.
• [2] CHALAJOUR F,SIYAHIAN A,HANLEY F L.The Role of Microenvironment in Preserving the Potency of Adult Porcine Pulmonary Valve Stem Cells In Vitro[J].Int J Stem Cells,2018,11(1):121-130.
• [3] NAGATA T,SHIMADA Y,SEKINE S,et al.Prognostic significance of NANOG and KLF4 for breast cancer[J].Breast Cancer,2014,21(1):96-101.
• [4] MKA M A,HUSSIN H,VEERAKUMARASIVAM A,et al.Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder[J].Malays J Pathol,2017,39(3):227-234.
• [5] LIANG C,ZHANG K,GE H,et al.Prognostic and clinicopathological value of Nanog in hepatocellular carcinoma:A meta-analysis[J].Clin Chim Acta,2018(477):24-31.
• [6] 张徐,徐梦,刘叶,等.干细胞因子Nanog在肿瘤中的研究进展[J].肿瘤防治研究,2016,43(4):295-299.
• [7] 梁军,杨波,吴小华.肿瘤干细胞标志物CD117在上皮性卯巢癌血管生成拟态中的表达及意义[J].肿瘤,2016,36(1):70-76.
• [8] SUN S,PAN X,ZHAO L,et al.The Expression and Relationship of CD68-Tumor-Associated Macrophages and Microvascular Density With the Prognosis of Patients With Laryngeal Squamous Cell Carcinoma[J].Clin Exp Otorhinolaryngol,2016,9(3):270-277.
• [9] WEI L,ZHU S,LI M,et al.High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer[J].Front Immunol,2018,15(9):724.
• [10] BALAN R A,CRUNTU I D,GIU?C S E,et al.Immunohistochemical significance of ER alpha,inhibin A,calretinin,and Ki67 expression in granulosa cell ovarian tumors[J].Rom J Morphol Emyol,2017,58(3):753-760.
• [11] ENER E,IPAL S,GUNDO D C.Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast[J].Turk Patoloji Derg,2016,32(3):164-170.
• [12] CHAMBERS I,COLBY D,ROBERTSON M,et al.Functional expression cloning of Nanog,a pluripotency sustaining factor in embryonic stem cells[J].Cell,2003,113(5):643-655.
• [13] GWAK J M,KIM M,KIM H J,et al.Expression of embryonal stem cell transcription factors in breast cancer:Oct4 as an indicator for poor clinical outcome and tamoxifen resistance[J].Oncotarget,2017,8(22):36305-36318.
• [14] HAN M L,WANG F,GU Y T,et al.MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis:By down-regulating NANOG[J].Biomed Pharmacother,2016,8(10):304-310.
• [15] WATANABE M,OHNISHI Y,INOUE H,et al.NANOG expression correlates with differentiation,metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma[J].Oncol Lett,2014,7(1):35-40.
• [16] THIAGARAJAN P S,SINYUK M,TURAGA S M,et al.Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase[J].Nat Commun,2018,9(1):578.
• [17] 吴义春,蔡逗逗,汪晓庆,等.肿瘤血管生成方式的研究进展(综述)[J].安徽卫生职业技术学院学报,2017,16(2):107-109.
• [18] VIALLARD C,LARRIVéE B.Tumor angiogenesis and vascular normalization:alternative therapeutic targets[J].Angiogenesis,2017,20(4):409-426.
• [19] RIBATTI D,NICO B,RUGGIERI S,et al.Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer[J].Transl Oncol,2016,9(5):453-457.
• [20] GUO J L,GU S Q,LI Y,et al.Evaluation of clinical significance of endoglin expression during breast cancer and its correlation with ER and PCNA[J].Eur Rev Med Pharmacol Sci,2017,21(23):5402-5407.